ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical TrialGlobeNewsWire • Wednesday
ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 11/14/24
ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 DiabetesGlobeNewsWire • 11/05/24
ZyVersa Therapeutics Highlights Review Article Supporting the Need for Drug Therapies to Treat the Inflammation of Obesity in Addition to Weight Loss DrugsGlobeNewsWire • 10/29/24
ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative DiseasesGlobeNewsWire • 10/22/24
ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Development Plans for Inflammasome ASC Inhibitor IC 100 Over the Next Nine MonthsGlobeNewsWire • 10/17/24
ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured Guest on The Big Biz Show to Discuss Current Trends in the Obesity Drug Market and the Potential Role of Inflammasome InhibitorsGlobeNewsWire • 10/15/24
ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic ComplicationsGlobeNewsWire • 10/07/24
ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 08/09/24
ZyVersa Therapeutics Announces Published Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic InflammationGlobeNewsWire • 08/07/24
ZyVersa Therapeutics Announces Published Data Demonstrating That Plasma Levels of Inflammasome ASC Show Promise as Biomarker of Early Cognitive Changes in Older AdultsGlobeNewsWire • 07/29/24
ZyVersa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome ASC Inhibitor IC 100GlobeNewsWire • 07/25/24
ZyVersa Therapeutics Announces Publication Demonstrating that Inflammasome ASC Inhibitor IC 100 Restored Retinal Structure and Function in a Retinopathy of Prematurity Animal ModelGlobeNewsWire • 07/18/24
ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 05/15/24
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International ConventionGlobeNewsWire • 05/14/24
ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer's DiseaseGlobeNewsWire • 04/29/24
ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with DiabetesGlobeNewsWire • 04/04/24
ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 03/25/24
ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator™ VAR 200 in Patients with Diabetic Kidney DiseaseGlobeNewsWire • 03/18/24
ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga's Virtual Healthcare Summit 2024 on March 20, 2024GlobeNewsWire • 03/14/24
ZyVersa Therapeutics Generated Approximately $2.7 Million From Exercise of Warrants Following Excitement Around News That Inflammasome Inhibitors Have Potential to Effectively Treat ObesityGlobeNewsWire • 02/29/24
ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100's Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its ComplicationsGlobeNewsWire • 02/28/24
